-
Mashup Score: 0Mosunetuzumab Monotherapy Yields Notable Efficacy, Manageable Safety for R/R DLBCL, Including for Patients With Prior CAR T-Cell Therapy - 7 month(s) ago
Mosunetuzumab monotherapy demonstrated strong efficacy and a manageable safety profile among patients with relapsed/refractory diffuse large B-cell lymphoma, including those previously treated with CAR T-cell therapy.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation - 7 month(s) ago
Autologous haematopoietic stem-cell transplantation (HSCT) involves collecting the stem cells of a patient, administering high-dose chemotherapy or radiation to eradicate the underlying haematological disease, and then reinfusing the collected stem cells to restore bone marrow. This procedure allows for the administration of high-dose chemotherapy while minimising damage to the bone marrow and immune system. Autologous HSCT has shown success in achieving complete remission and even long-term survival for some lymphoma subtypes.
Source: www.thelancet.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#Hematology Beyond remission: secondary primary malignancies in patients with #lymphoma after autologous haematopoietic stem-cell transplantation #ASCT - @TheLancetHaem by @AnnaSureda5 & @Evadodo23 #lymsm #bmtsm #survonc https://t.co/OjMFdjf9pY
-
-
Mashup Score: 0
High-dose chemotherapy and autologous HSCT was associated with an increased risk of non-melanoma skin cancer and myelodysplastic syndrome or AML but not with increased risk of solid tumours in patients treated for lymphoma. These findings are relevant for future individualised risk–benefit assessments when choosing between high-dose chemotherapy and autologous HSCT and chimeric antigen receptor T-cell therapy in this setting.
Source: www.thelancet.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#Hematology Second primary malignancies in patients with #lymphoma in Denmark 🇩🇰 after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation #ASCT: a population-based, retrospective cohort study - @TheLancetHaem #lymsm https://t.co/a4nWHWHbal
-
-
Mashup Score: 1Overall survival of cHL patients who progress after autologous stem cell transplant: results in novel agent era. - 7 month(s) ago
Key Points. Overall survival of cHL patients who progress after autologous stem cell transplant approached 9.5 years in novel agent era.Patients who receive CPI
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
#Hematology Overall survival of cHL #Hodgkin #lymphoma patients who progress after autologous stem cell transplant #ASCT: results in novel agent era | @BloodJournal Advances | American Society of Hematology @ASH_hematology #lymsm #bmtsm https://t.co/h90jp2Ffu4
-
-
Mashup Score: 0
Roland Walter, MD, PhD, and Johannes Schetelig, MD, debated on the sequencing of allogeneic stem cell transplant in patients with relapsed or refractory acute myeloid leukemia.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
During #SOHO23, Roland Walter, MD, PhD, and Johannes Schetelig, MD, debated on the sequencing of #ASCT in patients with R/R #AML. #leusm | @RolandBWalter @fredhutch @Medizin_TUD https://t.co/jEzV11ru4E
-
-
Mashup Score: 0Should ASCT be Standard of Care for Frontline Treatment of Patients With Multiple Myeloma? - 9 month(s) ago
C. Ola Landgren, MD, PhD, participated in a debate on whether melphalan plus ASCT after induction therapy should continue to be the standard of care in frontline treatment of patients with multiple myeloma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting #GDUHem, C. Ola Landgren, MD, PhD, argued that #ASCT should not continue as the standard of care, including clinical benefit and quality of life in his argument. https://t.co/mUhjr6piax @DrOlaLandgren https://t.co/YFMjOybevz
-
-
Mashup Score: 0Improving Inpatient Ambulation Remains a Critical Issue in Supporting Patients Posttransplant - 10 month(s) ago
Sarah Low RN, MSN, OCN, CMSRN; and Claudia Maldonado-Howell, RN, MSN, FNP, BS, CMSRN, highlight the importance of improving inpatient ambulation for transplant patients.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Sarah Low, RN, MSN, OCN, CMSRN; and Claudia Maldonado-Howell, RN, MSN, FNP, BS, CMSRN, highlight the importance of improving inpatient ambulation for transplant patients. #oncology #nursing #ASCT @CedarsSinai https://t.co/obL5xuirbO
-
-
Mashup Score: 0Improving Inpatient Ambulation Remains a Critical Issue in Supporting Patients Posttransplant - 10 month(s) ago
Sarah Low RN, MSN, OCN, CMSRN; and Claudia Maldonado-Howell, RN, MSN, FNP, BS, CMSRN, highlight the importance of improving inpatient ambulation for transplant patients.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Sarah Low RN, MSN, OCN, CMSRN; and Claudia Maldonado-Howell, RN, MSN, FNP, BS, CMSRN, highlight the importance of improving inpatient ambulation for transplant patients. #oncology #nursing #ASCT @CedarsSinai https://t.co/kzSFZYVbqv
-
-
Mashup Score: 0Improving Inpatient Ambulation Remains a Critical Issue in Supporting Patients Posttransplant - 10 month(s) ago
Sarah Low RN, MSN, OCN, CMSRN; and Claudia Maldonado-Howell, RN, MSN, FNP, BS, CMSRN, highlight the importance of improving inpatient ambulation for transplant patients.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Improving Inpatient Ambulation Remains a Critical Issue in Supporting Patients Posttransplant #oncology #nursing #ASCT @CedarsSinai https://t.co/eJZ5WpBm2z
-
-
Mashup Score: 1
Sarah Low RN, MSN, OCN, CMSRN; and Claudia Maldonado-Howell, RN, MSN, FNP, BS, CMSRN, discuss their research on wearable technology.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Watch Now: Sarah Low RN, MSN, OCN, CMSRN, discusses how the rise of wearable technology gives nurses more opportunities to creatively interact with and motivate patients. #ambulation #oncology #nursing #ASCT #ONSCongress @CedarsSinai Link: https://t.co/6Z0xTBhyhE https://t.co/8bOTwbavaz
-
Dr Nancy Bartlett stated, "This manageable safety profile makes it appealing for specific patient groups, such as elderly or unfit patients with previously untreated #DLBCL, patients who are not candidates for #ASCT or CAR-T therapy." https://t.co/3tNS8vbrQv @nancybartlettMD https://t.co/DDJWzoZKdn